Targeting interleukin (IL)-4/IL-13 in immune checkpoint inhibitor-induced bullous pemphigoid: a cautionary note on the beneficial effect of T helper 2 immunity in melanoma and immunotherapy

The use of dupilumab has been suggested in the treatment of immune checkpoint inhibitor (ICI)-induced bullous pemphigoid. In this letter, we express caution with the targeted inhibition of the Th2 pathway given current evidence suggesting the beneficial effect of the Th2 response, particularly eosinophilia, to ICI responses, particularly in melanoma.

Automated summary

The use of dupilumab in the treatment of ICI-induced bullous pemphigoid is suggested, but caution is advised regarding the targeted inhibition of the Th2 pathway due to evidence suggesting the beneficial effect of the Th2 response, particularly eosinophilia, on ICI responses, especially in melanoma.